Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Pulmonary Arterial Hypertension (PAH) (W...
Phase NA
Enrollment 61
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Pulmonary arterial hypertension (PAH) is a progressive condition with high morbidity, frequent hospitalizations, and risk of right heart failure. Despite advances in treatment, poor adherence remains a major challenge. This randomized controlled study assesses whether remote monitoring can improve treatment adherence, clinical outcomes, and side effect management in PAH patients on oral therapy.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Telemedicine-Based Adherence Support — The intervention consists of biweekly teleconsultations for six months, conducted by healthcare professionals, focusing on medication adherence, patient education, side effect management, and remote support for individuals with pulmonary arterial hypertension (PAH). Patients will receive structured guidance on treatment adherence, tailored counseling, and real-time problem-solving strategies. The goal is to improve adherence to oral PAH therapy and enhance clinical outcomes compared to standard care.

Primary Outcomes

  • Medication Adherence (Martín-Bayarre-Grau Scale - MBG) (24 weeks (end of study period))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-05-07
Completion: 2028-04
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 61 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Sao Paulo General Hospital
Contact Information
Study Contact:
Caio Fernandes, PhD
+55 11 2661-1548
caio.cesar@hc.fm.usp.br
Caio Fernandes, PhD
+55 11 2661-1548
caio.cesar@hc.fm.usp.br
InCor - Universidade de São Paulo
Interventions
  • Behavioral: Telemedicine-Based Adherence Support — The intervention consists of biweekly teleconsultations for six months, conducted by healthcare professionals, focusing on medication adherence, patient education, side effect management, and remote support for individuals with pulmonary arterial hypertension (PAH). Patients will receive structured guidance on treatment adherence, tailored counseling, and real-time problem-solving strategies. The goal is to improve adherence to oral PAH therapy and enhance clinical outcomes compared to standard care.
Study Locations (1 sites)
InCor - Universidade de São Paulo, São Paulo, São Paulo 05048000 Brazil
Eligibility Criteria
Inclusion Criteria: * Adults aged ≥18 years diagnosed with pulmonary arterial hypertension (PAH) (Group 1 of the WHO classification). * Stable oral PAH therapy (including endothelin receptor antagonists, phosphodiesterase-5 inhibitors, or prostacyclin pathway agents) for at least four weeks prior to enrollment. * Ability to participate in remote teleconsultations (access to a phone or internet). * Signed informed consent agreeing to study participation. Exclusion Criteria: * Severe cognitive impairment or psychiatric disorders that could affect adherence or study participation. * Inability to communicate via phone or telemedicine due to technical or personal constraints. * Concurrent participation in another interventional clinical trial that could interfere with outcomes. * Life expectancy \<6 months due to any condition unrelated to PAH. * Pregnancy or breastfeeding.
Conditions Alzheimer Disease, Depression
Phase NA
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Behavioural and psychological symptoms of dementia (BPSD), such as depression affect up to 90% patients with dementia. Non-pharmacological treatment of BPSD, can be difficult to access, require caregiver support, travel, and often have long waiting lists. Virtual reality (VR) is an innovative, portable, immersive, and accessible technology which can be used in-home. More information is required on the feasibility of using VR in-home with older adults with dementia. Our study will offer a 4-week program of 15-minutes sessions, twice per week nature-based VR program for BPSD delivered in-home by virtual reality (VR). Additionally, caregivers will have the option of taking part in the study and provide feedback regarding the VR intervention. If successful, this project has the potential to prolong aging in place for individuals with BPSD, as BPSD is a significant factor in institutionalization.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Other: nature-based virtual reality applications and videos — Participants will receive nature-based applications available on the Oculus platform, as well as nature-based 360 videos with the same content as the control group however in a 360 format.
  • Other: nature-based videos — Participants will receive YouTube links to watch nature-based videos on a device (e.g., a tablet).

Primary Outcomes

  • Tolerability of nature-based virtual reality (4 weeks)
  • Feasibility of nature-based virtual reality (4 weeks)
  • Acceptability of nature-based virtual reality (4 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-01-06
Completion: 2025-11-11
Eligibility
Age: 50 Years and older
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Centre for Addiction and Mental Health
Collaborators: St. Mary's Research Center, Canada
Principal Investigators:
  • HARMEHR SEKHON, PhD (PRINCIPAL_INVESTIGATOR) - CAMH and McGill/St. Mary's Research Centre
  • Eric Brown, MD (PRINCIPAL_INVESTIGATOR) - CAMH and UofT
Contact Information
Study Contact:
Ashnie Sukhu, BSc
(416) 535-8501
ashnie.sukhu@camh.ca
Ashnie Sukhu
ashnie.sukhu@camh.ca
Centre for Addictions and Mental Health (CAMH)
Interventions
  • Other: nature-based virtual reality applications and videos — Participants will receive nature-based applications available on the Oculus platform, as well as nature-based 360 videos with the same content as the control group however in a 360 format.
  • Other: nature-based videos — Participants will receive YouTube links to watch nature-based videos on a device (e.g., a tablet).
Study Locations (1 sites)
Centre for Addictions and Mental Health (CAMH), Toronto, Ontario L5V 2X3 Canada
Eligibility Criteria
Inclusion Criteria: * Clinical diagnosis of mild to early-moderate stage AD (including mixed dementia with AD) using the Diagnostic and Statistical Manual of Mental Disorders, 5th Ed. Criteria * Age of 50 years or older * Medical stability to participate in the trial * Patient Health Questionnaire score 5-14 * Investigator judgement on whether the participant is comfortable with technology * Access to WiFi and a smart device for connecting on WebEx and downloading the Fitbit and Muse applications * Have someone available to be present during all sessions Exclusion Criteria: * Unstable medical or psychiatric condition, including substance use based on an investigator opinion * Visual or hearing impairments that would impair participation * Patient Health Questionnaire score 15-27 and/or score of 1 or 2 in section E question 1 of the Cornell Scale for Depression in Dementia * Any other reason, which will make the study participation intolerable for the participant in the opinion of the study investigator

Taiwan Post-Stroke Disability Study

NCT06772194
Recruiting
Conditions Stroke, Dementia, Epilepsy, Depression
Phase Not Applicable
Enrollment 2000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Stroke remains a major health issue in Taiwan, being the fourth leading cause of death and the top cause of disability. While past research has focused on functional outcomes at three months post-stroke, stroke can cause a range of disabilities in areas such as motor function, swallowing, cognition, depression, and epilepsy. This study will investigate these disabilities by enrolling 2,000 acute stroke patients (both ischemic and hemorrhagic) from 10 medical centers across Taiwan. Data will be collected at three key points: at enrollment, three months, and twelve months post-stroke, using surveys, assessments, imaging, and blood samples. The aim is to examine the prevalence, risk factors, and long-term changes of post-stroke disabilities, ultimately seeking ways to reduce the health burden of stroke in Taiwan.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Number of patients with recurrent stroke, including ischemic and hemorrhagic stroke (3 & 12 month)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-10-21
Completion: 2028-09-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 2000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Taiwan University Hospital
Collaborators: National Taiwan University Hospital Hsin-Chu Branch, National Taiwan University Hospital, Yun-Lin Branch, Shin Kong Wu Ho-Su Memorial Hospital, Mackay Memorial Hospital, Chang Gung Memorial Hospital, National Cheng Kung University, Landseed Hospital, Taichung Veterans General Hospital, Taipei Veterans General Hospital, Taiwan, Tri-Service General Hospital (TSGH), AbbVie, Taipei Medical University Shuang Ho Hospital, Chi Mei Medical Hospital, Chang Gung Memorial Hospital, Keelung
Contact Information
Study Contact:
Chih-Hao Chen, Dotoral
+886-2-2312-3456
antonyneuro@gmail.com
Jiann-Shing Jeng, PhD
+886-2-23123456
jsjeng@ntu.edu.tw
Interventions
N/A
Study Locations (1 sites)
National Taiwan University Hospital, Taipei,, Taipei, Taiwan
Eligibility Criteria
Inclusion Criteria: 1. Ischemic stroke confirmed by MRI, or hemorrhagic stroke diagnosed by CT or MRI. 2. Age ≥ 18 years. 3. Pre-stroke modified Rankin Scale (mRS) score of 0, 1, or 2. 4. Post-stroke mRS score of 0, 1, 2, 3, or 4 at enrollment. 5. Able to undergo cognitive function screening and other scale assessments within 30 days post-stroke. Exclusion Criteria: 1. Transient ischemic stroke and subarachnoid hemorrhage. 2. Clear and severe psychiatric or emotional disorders before the stroke, including schizophrenia, major depressive disorder, and bipolar disorder. 3. History of clinical stroke within three months prior to enrollment. 4. Unable to communicate or cooperate for assessments due to severe aphasia. 5. Severe dementia prior to the stroke. 6. Pre-stroke modified Rankin Scale (mRS) score ≥ 3. 7. Post-stroke mRS score of 5 at enrollment. 8. History of cancer with an expected life expectancy of less than one year. 9. Expected life expectancy of less than one year due to other medical conditions. 10. Anticipated inability to complete a one-year follow-up. 11. Other situations deemed unsuitable for enrollment by the clinical investigator.
Conditions TNBC, Triple Negative Breast Cancer
Phase PHASE2
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study is to evaluate the efficacy and safety of QL1706 plus albumin-bound paclitaxel ± bevacizumab in 1L treatment of r/mTNBC

Design

Study type: Interventional Phases: Phase2 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: bevacizumab — bevacizumab
  • Drug: QL1706 — Bispecific antibody (bsAB) targeting PD-1 and CLTA-4
  • Drug: Nab paclitaxel — albumin-bound paclitaxel

Primary Outcomes

  • ORR by investigator (At baseline, at the time point of every 6 weeks, up to 1 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-10-09
Completion: 2028-12-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fudan University
Contact Information
Study Contact:
Wang Hongxia
021-64175590
whx365@126.com
Tao Zhonghua
13774315805
drtaozhh@126.com
Wang hoangxia
13524491606
whx365@126.com
Fudan University Shanghai Cancer Center
Interventions
  • Drug: bevacizumab — bevacizumab
  • Drug: QL1706 — Bispecific antibody (bsAB) targeting PD-1 and CLTA-4
  • Drug: Nab paclitaxel — albumin-bound paclitaxel
Study Locations (1 sites)
Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality 200032 China
Eligibility Criteria
Inclusion Criteria: 1. Voluntarily join this study and sign the informed consent form; 2. Female patients aged ≥18 years and ≤70 years old who had been dignosed with breast cancer; 3. According to the definition of the latest ASCO/CAP guidelines, histologically confirmed estrogen receptor negative (ER-) and progesterone receptor negative (PR-), human epidermal growth factor receptor 2 negative 4. For patients with locally advanced, recurrent or metastatic breast cancer who have not used any systematic treatment (it is allowed to accept adjuvant/neoadjuvant treatment, and the time from the last administration to recurrence and metastasis should be ≥ 6 months); 5. According to RECIST 1.1, there is at least one measurable lesion; 6. ECOG score: 0\~1; 7. Tumor tissue specimens that can be used for biomarker detection; 8. Adequate organ function (no blood components or cell growth factor drugs are allowed within 14 days before the first medication): (1) Absolute neutrophil count ≥1.5×109/L; (2) Platelets ≥100×109/L; (3) Hemoglobin ≥90 g/L; (4) Serum albumin ≥30 g/L; (5) Thyroid-stimulating hormone (TSH) ≤1×ULN (if abnormal, the FT3 and FT4 levels should be examined at the same time. If the FT3 and FT4 levels are normal, you can be included in the group); (6) Serum total bilirubin ≤1.5×ULN,if liver metastasis is present, ≤3ULN; (7) ALT and AST ≤2.5×ULN, if liver metastasis is present, ALT and AST ≤5ULN; (8) AKP≤2.5×ULN; Serum creatinine ≤1.5×ULN; (9) International normalized ratio (INR) ≤1.5 (not receiving anticoagulant therapy). Exclusion Criteria: * 1.The presence of any active autoimmune disease or a history of autoimmune disease (such as the following, but not limited to autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hypophysitis, vasculitis, nephritis, hyperthyroidism;Those who suffer from vitiligo or whose asthma has been completely relieved in childhood and do not need any intervention in adulthood can be included; asthma that requires medical intervention with bronchodilators cannot be included); 2.Are currently using immunosuppressants or systemic steroid therapy to achieve immunosuppression ((in dosing exceeding 10 mg daily of prednisone equivalent), and are still using it within 2 weeks before enrollment; 3.Severe allergic reactions to other monoclonal antibodies; 4. Known history or evidence of interstitial lung disease or active non-infectious pneumonia; 5.Known central nervous system metastasis; 6.Known additional malignant tumors within the past 5 years (except cured basal cell carcinoma of the skin and cervical cancer in situ); 7. The presence of uncontrolled hypertension (systolic blood pressure \&amp;gt;140mmHg or diastolic blood pressure \&amp;gt;90mmHg) or dignosis with hypertensive crisis or hypertensive encephalopathy. Known history of hypertension are admitted to the study if their blood pressure is controlled below this standard and maintained with antihypertensive therapy. 8.Patients with a history of severe cardiovascular and cerebrovascular disease, including but not limited to: (1) NYHA grade 2 or above heart failure (2) Unstable angina (3) Myocardial infarction within 1 year (4) Clinically significant supraventricular infarction or ventricular arrhythmia requiring treatment or intervention (5) QTc\&amp;gt;450ms (male); QTc\&amp;gt;470ms (female); 9.Those who are receiving thrombolysis or anticoagulation therapy; prophylactically use of low-dose aspirin and low-molecular-weight heparin are allowed; 10.Have clinically significant bleeding symptoms or a clear bleeding tendency within 3 months before enrollment; if fecal occult blood is positive in the screening, it should be re-examined. If it is still positive after the reexamination, a gastroscopy is required; 11.The tumor invades vital blood vessels, or a high possibility that the cancer will invade important blood vessels in the future study period, which may lead to fatal bleeding; 12.Patients with pleural effusion, ascites or pericardial effusion that require drainage can be enrolled if the researcher assesses that the symptoms are stable after drainage; 13.Arterial/venous thrombosis events that occurred within 6 months before enrollment, such as cerebrovascular accidents (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis and pulmonary embolism; 14.Major vascular disease (for example, aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months before the start of study treatment; 15.Urine routine shows urine protein ≥ ++ and confirmed 24-hour urine protein amount \&amp;amp;amp;gt;1.0 g; 16.Suffering from active infection, unexplained fever ≥38.5℃ within 7 days before taking the drug, or baseline white blood cell count \&amp;amp;amp;gt;15×109/L; 17.Those with congenital or acquired immune deficiency (such as HIV infection); those who are hepatitis B surface antigen (HBsAg) positive and hepatitis B virus deoxyribonucleic acid (HBV DNA) ≥ 2000 IU/ml, or hepatitis C virus antibody positive; Have received live vaccines less than 4 weeks before study medication or may be vaccinated during the study period; 18.In the judgment of the researcher, the patient has other factors that may affect the study results or cause the study to be terminated midway, such as alcoholism, drug abuse, other serious diseases (including mental illness) that require combined treatment, and serious laboratory tests. Abnormalities, accompanied by family or social factors, may affect the patient\&amp;amp;amp;#39;s safety.
Conditions Post-traumatic Stress Disorder (PTSD), A...
Phase NA
Enrollment 300
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study examines if playing Tetris prevents the development of Post-traumatic stress disorder or related anxiety and depressive symptoms. The investigators recruit 300 participants in total in Greece and in the Netherlands. The participants are immigrants who have applied for asylum at any point in the past. The participants are asked to answer three questionnaires (on Post-traumatic stress disorder, related anxiety and depressive symptoms, and post-migration living difficulties) on a recurring basis - once every 4 weeks, 12 times in total. Half of the participants (treatment group) are randomly selected to play Tetris after completing the questionnaires. Participants in the treatment group are instructed to play Tetris for at least 15 minutes while trying to remember bad things that recently happened to them. Tetris is administered at three instances and participants in the treatment group are encouraged to play Tetris in case of experiencing any traumatic events or having any intrusive memories during the course of the study.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Tetris — Randomly selected participants (migrants) are asked to play Tetris for at least 15 minutes on several occasions. These participants are asked while playing Tetris to try and remember bad events that recently happened to them. The participants play the classic version of the Tetris game directly on their mobile phone.
  • Other: No intervention — Participants do not receive any intervention.

Primary Outcomes

  • Post-traumatic stress disorder (From enrolment to the end of the study (40 weeks))
  • Anxiety and depression symptoms (From enrolment to the end of the study (40 weeks))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-12-17
Completion: 2025-12-07
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Tilburg University
Collaborators: Stichting tot steun VCVGZ
Contact Information
Study Contact:
Mario Braakman, Prof.
+31629514366
Mario.Braakman@tilburguniversity.edu
Tihomir Sabchev, Dr.
t.y.sabchev@tilburguniversity.edu
Mario Braakman, Prof.
+31629514366
Mario.Braakman@tilburguniversity.edu
Upinion (online)
Interventions
  • Behavioral: Tetris — Randomly selected participants (migrants) are asked to play Tetris for at least 15 minutes on several occasions. These participants are asked while playing Tetris to try and remember bad events that recently happened to them. The participants play the classic version of the Tetris game directly on their mobile phone.
  • Other: No intervention — Participants do not receive any intervention.
Study Locations (2 sites)
Upinion (online), The Hague, NL 2511 CJ Greece
Upinion/the humanity Hub, The Hague, NL 2511 CJ Netherlands
Eligibility Criteria
Inclusion Criteria: * Arabic-speaking immigrants of any gender who have applied for asylum in Greece or in the Netherlands, regardless of the outcome of their asylum application and their current residency status (rejected asylum seekers, recognized refugees, undocumented migrants). Exclusion Criteria: * Minors (under the age of 18).
Conditions Major Depressive Disorder (MDD), Major D...
Phase Not Applicable
Enrollment 200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this observational study is to learn about remote mental health monitoring technology for adults with treatment-resistant depression. The main question it aims to answer is: are digital mental health monitoring tools (an electronic data capture platform and wearable device (e.g., smartwatch or smart-ring)) feasible to implement alongside clinical treatment for depression? The secondary aim of this study is to inform preliminary clinical parameters for larger, definitive studies. Participants receiving neuropsychiatric treatment (repetitive transcranial magnetic stimulation, intravenous ketamine, or electroconvulsive therapy) as part of their regular medical care for treatment-resistant depression in the Interventional Psychiatry Program will have their clinical assessment data entered into a digital platform and will wear an accessory-based wearable device for the duration of treatment.

Design

Study type: Observational Observational model: Case Only Time perspective: Retrospective

Primary Outcomes

  • Feasibility (From Screening and Baseline Visit (Day 0) to last treatment day (approximately 2-8 weeks depending on treatment group))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-12-16
Completion: 2026-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Unity Health Toronto
Collaborators: University of Toronto, Toronto Metropolitan University
Principal Investigators:
  • Dr. Srihar Krishnan, Ph.D., Peng., F.C.A.E. (STUDY_CHAIR) - Toronto Metropolitan University
  • Dr. Wendy Lou, Ph.D. (STUDY_CHAIR) - Dalla Lana School of Public Health, University of Toronto
Contact Information
Study Contact:
Dr. Venkat Bhat, M.D., F.R.C.P.C.
416-360-4000
venkat.bhat@unityhealth.to
Dr. Karisa Parkington, Ph.D.
416-360-4000
karisa.parkington@unityhealth.to
Dr. Venkat Bhat, M.D., F.R.C.P.C.
416-360-4000
venkat.bhat@unityhealth.to
St. Michael's Hospital, Unity Health Toronto
Interventions
N/A
Study Locations (1 sites)
St. Michael's Hospital, Unity Health Toronto, Toronto, Ontario M5B 1W8 Canada
Eligibility Criteria
Inclusion Criteria: * Adults (aged 18+) who are capable of giving informed consent * Patients meeting diagnostic criteria for major depressive disorder (MDD) without psychotic symptoms according to the DSM-5 * Currently experiencing a major depressive episode (MDE) * Montgomery-Asperg Depression Rating Scale (MADRS) score greater than 20 at screening * Patients meeting criteria for treatment-resistant depression (TRD): failure of 2 or more adequate trials of antidepressant therapy of adequate dose and duration during the current episode * Enrollment in one of the treatment modalities (rTMS, IVK, or ECT) at the Interventional Psychiatry Program at St. Michael's Hospital, Unity Health Toronto * Ownership of a smartphone (for participants using wearable devices) Exclusion Criteria: * Individuals without Internet access (required to access study platforms) * Medication changes, aside from the treatment received through the IPP, one month (28 days) before screening, or during the entire duration of treatment (variable based on treatment arm) * Participants who do not speak English fluently enough to successfully communicate study information, answer questions accurately, and/or obtain informed consent

LHC-CIDI-5 in Hong Kong

NCT06804525
Recruiting
Conditions Major Depressive Episode (MDE), Major De...
Phase Not Applicable
Enrollment 2500
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The World Health Organization Composite International Diagnostic Interview-5th (CIDI-5) is a standardized diagnostic tool used to assess the prevalence of mental and substance use disorders over varying time frames (30 days, 12 months, and lifetime) based on the diagnostic criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) and International Classification of Diseases 10th edition (ICD-10). However, retrospective measurements like the CIDI-5 are susceptible to recall bias, especially for the lifetime experience, which can hinder the reporting accuracy with mental disorders. To mitigate this issue, the life history calendar (LHC) was introduced as an aid to assist respondents in recalling the timing of life events, enhancing the ability of the CIDI-5 to measure the lifetime prevalence of mental disorders. The LHC is a grid structure with columns representing time units and rows representing life domains under study. In a study conducted in Nepal, combining the CIDI-5 with the LHC resulted in a significant increase in the detection of mental disorders compared to using the CIDI-5 alone. This approach did not lead to an increase in false positives after clinical validation. This experiment aims to adapt a Hong Kong version of the LHC based on the Nepalese model and evaluate the effectiveness of the LHC-assisted CIDI-5 (LHC-CIDI-5) compared to the CIDI-5 alone in assessing mental disorders.

Design

Study type: Observational Observational model: Ecologic Or Community Time perspective: Cross Sectional

Interventions / Regimen

  • Diagnostic Test: CIDI-5 — The World Health Organization Composite International Diagnostic Interview-5th (CIDI-5) is a standardized diagnostic tool used to assess the prevalence of mental and substance use disorders over varying time frames (30 days, 12 months, and lifetime) based on the diagnostic criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) and International Classification of Diseases 10th edition (ICD-10) . Trained interviewers will administrate selected modules from the Hong Kong version of the CIDI-5 in a computer-assisted personal interview to measure the outcomes.
  • Diagnostic Test: LHC-CIDI-5 — The interviewer will start by asking the respondent's age and significant personal experiences, which is expected to take 15 minutes. Remembering and recording the experiences provide cognitive engagement and information which can further serve as memory cues for respondents in the following screening of CIDI-5. Subsequently, the respondents will proceed to the screening section for CIDI-5 and will refer to the completed calendar from the LHC section when they are asked to report lifetime experience or age-of-onset for mental disorders. Trained interviewers will conduct all interviews in a computer-assisted personal interview. To validate the diagnoses in the LHC-CIDI-5 group, clinical re-interviews for MDD, GAD, and PTSD will be conducted by a trained mental health professional with previous experience using DSM-5.

Primary Outcomes

  • Depression (Immediately following intervention or recruitment)
  • Persistent Depression (Immediately following intervention or recruitment)
  • Self Harm (Immediately following intervention or recruitment)
  • High Mood (Immediately following intervention or recruitment)
  • Worry and Anxiety (Immediately following intervention or recruitment)
  • Anger Attacks (Immediately following intervention or recruitment)
  • Panic Attacks (Immediately following intervention or recruitment)
  • Obsessions and Compulsions (Immediately following intervention or recruitment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-01-18
Completion: 2027-04
Eligibility
Age: 25 Years and older
Sex: ALL
Volunteers: Not specified
Enrollment: 2500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The University of Hong Kong
Principal Investigators:
  • Michael Y. Ni, MD (PRINCIPAL_INVESTIGATOR) - The University of Hong Kong
Contact Information
Study Contact:
Yoona Kim, PhD
852+39179109
yoonak@hku.hk
Rusi Long, MHS
852+39102308
rlong36@hku.hk
Yoona Kim, PhD
852+39179109
yoonak@hku.hk
The University of Hong Kong
Interventions
  • Diagnostic Test: CIDI-5 — The World Health Organization Composite International Diagnostic Interview-5th (CIDI-5) is a standardized diagnostic tool used to assess the prevalence of mental and substance use disorders over varying time frames (30 days, 12 months, and lifetime) based on the diagnostic criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) and International Classification of Diseases 10th edition (ICD-10) . Trained interviewers will administrate selected modules from the Hong Kong version of the CIDI-5 in a computer-assisted personal interview to measure the outcomes.
  • Diagnostic Test: LHC-CIDI-5 — The interviewer will start by asking the respondent's age and significant personal experiences, which is expected to take 15 minutes. Remembering and recording the experiences provide cognitive engagement and information which can further serve as memory cues for respondents in the following screening of CIDI-5. Subsequently, the respondents will proceed to the screening section for CIDI-5 and will refer to the completed calendar from the LHC section when they are asked to report lifetime experience or age-of-onset for mental disorders. Trained interviewers will conduct all interviews in a computer-assisted personal interview. To validate the diagnoses in the LHC-CIDI-5 group, clinical re-interviews for MDD, GAD, and PTSD will be conducted by a trained mental health professional with previous experience using DSM-5.
Study Locations (1 sites)
The University of Hong Kong, Hong Kong, Hong Kong
Eligibility Criteria
Inclusion Criteria: * All household members aged 25 years old and over are randomly sampled from the Census and Statistics Department List of Quarters * Live in the address sampled from the Census and Statistics Department List of Quarters * Reside in Hong Kong for at least six months in the past year * Able to read and communicate in Chinese or English * Without linguistic or cognitive difficulties Exclusion Criteria: * Domestic workers
Conditions Anesthesia, Cerebral Blood Flow, Regiona...
Phase NA
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

During anesthesia, blood pressure-raising medications are often required to achieve an adequate blood pressure level. However, there is limited knowledge about what constitutes an adequate blood pressure to ensure sufficient blood flow to the brain. This project aims to map the relationship between blood pressure and brain blood flow using an MRI scanner. The results will contribute to a better understanding of this relationship and lead to improved management of brain blood flow during surgery on anesthetized patients. How does the project work? Day 1 Before planned surgery, participants will meet with an anesthesiologist for information and assessment. An MRI scan of the brain will be conducted while participants are awake. The MRI examination has no side effects or risks. The space inside the MRI scanner is tight, especially around the head. If discomfort is experienced, the examination will be stopped immediately. The machine is noisy, so hearing protection will be provided, and communication with staff will be possible throughout the examination. The scan takes approximately 30 minutes, during which participants only need to lie still and relax. Day 2 After planned surgery, an anesthesiologist and an anesthesia nurse will transfer participants to the MRI scanner while still under anesthesia. Participants will not be woken up between surgery and the MRI scan; instead, transportation will occur while still anesthetized, following standard hospital procedures. Participants will remain under the same anesthetic drugs as during the surgery. The same blood pressure-raising medication, norepinephrine, will be continuously used. No additional drugs, beyond those necessary for normal anesthesia, will be administered before the MRI examination. The entire project will take about 1.5 hours in addition to the surgery. If an arterial catheter (a blood pressure monitor via an artery in the wrist) is not already in place, one will be inserted while participants are asleep. Before the MRI examination: Baseline examination - If any abnormalities are detected, the scan will be stopped, and follow-up by a doctor will occur. Blood pressure increase - Blood pressure will be raised by approximately 30% (equivalent to mild physical activity, such as jogging). Follow-up scan at the higher blood pressure level. Blood pressure returns to normal. All blood pressure levels will remain within clinically acceptable ranges for anesthetized patients and will be regulated with the same medication as used during the surgery. After the MRI: Participants will be woken up in the anesthesia preparation room next to the MRI scanner. The arterial catheter will be removed before awakening. Participants will be transported to the postoperative unit for monitoring. The surgeon responsible for care will determine the discharge time. Possible Risks and Side Effects of Participation Transporting an anesthetized patient for an MRI scan outside the operating room carries…

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Other: Blood pressure elevation — Increasing systemic blood pressure for measurement of cerebral blood flow changes

Primary Outcomes

  • Cerebral blood flow (1 hour)
  • rSO2 (1 hour)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-12-06
Completion: 2027-06-01
Eligibility
Age: 50 Years and older
Sex: ALL
Volunteers: true
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Umeå University
Collaborators: Region Västerbotten
Contact Information
Study Contact:
Laleh Zarrinkoob, MD, PhD
+46707567067
laleh.zarrinkoob@umu.se
Laleh Zarrinkoob, MD, PhD
+46707567067
laleh.zarrinkoob@umu.se
Umeå University Hospital
Interventions
  • Other: Blood pressure elevation — Increasing systemic blood pressure for measurement of cerebral blood flow changes
Study Locations (1 sites)
Umeå University Hospital, Umeå, Sweden
Eligibility Criteria
Inclusion Criteria: * ASA classification 1-3 * BMI 18,5-29.9 * MMSE \> 23 * Elective surgery planned. Exclusion Criteria: \- Pacemaker or other contraindications for MRI.
Conditions Diabetes Mellitus, Pancreatic Cancer, Ad...
Phase NA
Enrollment 5000
Locations 31 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this interventional study is to evaluate if the novel diagnostic blood test, called Avantect can early detect pancreatic cancer in patients diagnosed with type 2 diabetes or with elevated sugar levels within the last 200 days. Participants will: * attend 3 study visits over 12 months time * provide a blood sample at each study visit * complete an anxiety questionnaire at each visit.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Device: Avantect Pancreatic Cancer Test — Avantect test

Primary Outcomes

  • Sensitivity of the Avantect test (The final analysis will be carried out after 3-year follow up data has been collected for all 5,000 participants.)
  • Specificity of the Avantect test (The final analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-05-21
Completion: 2032-07
Eligibility
Age: 50 Years and older
Sex: ALL
Volunteers: false
Enrollment: 5000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospital Southampton NHS Foundation Trust
Collaborators: ClearNote Health
Contact Information
Study Contact:
SAFE-D Trial Manager
+442381205154
safed@soton.ac.uk
Anson-Wisniewska
02380215154
safed@soton.ac.uk
Maidstone and Tunbridge Wells NHS Trust
Anson-Wisniewska
02380215154
safed@soton.ac.uk
Balance Street Health Centre
Interventions
  • Device: Avantect Pancreatic Cancer Test — Avantect test
Study Locations (31 sites)
Ashfields Primary Care Centre, Sandbach, Cheshire CW11 1EQ United Kingdom
Maidstone and Tunbridge Wells NHS Trust, Maidstone, Kent ME16 9QQ United Kingdom
Balance Street Health Centre, Uttoxeter, Kent ST14 8JG United Kingdom
Forest Medical Group, Leicester, Leicester Forest East LE3 3LW United Kingdom
South Leicestershire Medical Group, Kibworth Beauchamp, Leicestershire LE8 0LG United Kingdom
Peel Croft Surgery, Burton-on-Trent, Staffordshire DE14 3RH United Kingdom
Kingswinford Medical Practice, Kingswinford, Staffordshire DY6 8DN United Kingdom
Park Medical Centre, Leek, Staffordshire ST13 6QR United Kingdom
Trinity Court Surgery, Stratford-upon-Avon, Staffordshire CV37 6HJ United Kingdom
Brockwood Medical Practice, Brockham, Surrey RH3 7NJ United Kingdom
Eligibility Criteria
Inclusion Criteria: * 50 - 84 years of age at the time of enrolment (within year of birth, not month of birth) * Confirmed type 2 DM diagnosis established within the last 200 days or an initial elevated HbA1c ≥ 48 mmol/mol or 6.5% obtained within the last 200 days. This includes people who have a first elevated HbA1c (≥ 48 mmol/mol or 6.5%) within the last 200 days, even if subsequent HbAc1 measurements return to the the normal range. * Willing to provide up to 30 mL of blood for each study visit * Willing and eligible to undergo MRI or CT scan * Understands the study process and is willing to take part in the study and sign the informed consent form Exclusion Criteria: * Prior type I or type II DM diagnosis or an initial HbA1c ≥ 48 mmol/mol or 6.5% obtained prior to the 200-day inclusion window, except gestational elevated HbA1c. * A history of pancreatic cancer, pancreatic neuroendocrine tumour (pNET) or Pancreatitis * Under investigation for or confirmed pancreatic cancer * Under investigation/surveillance for pancreatic cyst * Any known pancreatic surgery (not including ERCP), or other major surgery requiring anaesthesia within 3 months * Any invasive solid or haematological cancer in the past 3 years, including cancer recurrence after treatment in the last 3 years * BMI \> 40 at the time of consent * Blood transfusion within 1 month * Solid organ transplant recipient * Currently pregnant * Needing dialysis
Conditions Working Memory, Mild to Moderate Depress...
Phase PHASE2
Enrollment 38
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Cognitive deficits, including working memory deficits, are often present in depression and there are currently no effective pharmacological treatments targeting working memory deficits. Papassotiropoulos et al. (2024) has recently demonstrated that fampridine, a potassium channel blocker, can enhance working memory in healthy individuals with lower baseline performance, suggesting it may hold potential for addressing cognitive deficits in clinical populations. The primary aim of this study is to evaluate whether fampridine improves working memory performance in mild to moderate depression

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Crossover Primary purpose: Basic Science Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Fampridine SR — Active study medication consists of 15 tablets of fampridine SR 10 mg formulated for oral administration taken in the morning and evening 12 h apart without food. Tablets must be administered whole.
  • Other: Placebo — no active substance

Primary Outcomes

  • High-load working memory performance. (Before first intake of study medication and after last intake of study medication of the 7.5-days-treatment periods)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-05-22
Completion: 2026-07
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 38 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Basel
Collaborators: Clinical Trial Unit, University Hospital Basel, Switzerland
Principal Investigators:
  • Dominique de Quervain, Prof. MD (STUDY_CHAIR) - Research Cluster Molecular and Cognitive Neurosciences
  • Andreas Papassotiropoulos, Prof.MD (STUDY_CHAIR) - Research Cluster Molecular and Cognitive Neurosciences
  • Annette Bruehl, Prof.MD (STUDY_CHAIR) - Zentrum für Affektive -, Stress- und Schlafstörungen & Zentrum für Alterspsychiatrie UPK Basel
Contact Information
Study Contact:
Christiane Gerhards, MD
+41 61 207 0244
christiane.gerhards@unibas.ch
Dominique de Quervain, Prof.
+41 61 207 02 37
dominique.dequervain@unibas.ch
University of Basel, Reserach Cluster Molecular and Cognitive Neurosciences
Andreas Papassotiropoulos, Prof
+41 61 207 05 88
andreas.paps@unibas.ch
University of Basel, Reserach Cluster Molecular and Cognitive Neurosciences
Interventions
  • Drug: Fampridine SR — Active study medication consists of 15 tablets of fampridine SR 10 mg formulated for oral administration taken in the morning and evening 12 h apart without food. Tablets must be administered whole.
  • Other: Placebo — no active substance
Study Locations (1 sites)
University of Basel, Reserach Cluster Molecular and Cognitive Neurosciences, Basel, Canton of Basel-City 4055 Switzerland
Eligibility Criteria
Inclusion Criteria: * Male or female * Major depressive episode confirmed by the Mini-DIPS. Currently mild to moderate (MADRS: 7-30). * Normotensive (BP: 90/60mmHg - 140/90mmHg). Sufficiently treated hypertensive subjects will be included. * BMI: 19 - 34,9 kg/m2 * Age: 18 - 55 years * Fluent in German * IC as documented by signature Exclusion Criteria: * Contraindications to the class of drugs under study, e.g. known hypersensitivity or allergy to 4-aminopyridine * Use of potassium channel blockers within the last 3 months * Treatment with OCT 2 inhibitors and -substrates (e.g. cimetidine, propranolol) * Treatment with antidepressants or antipsychotics within the last 3 months and throughout the study period * Current intake of psychoactive drugs (e.g. benzodiazepines, antidepressants, neuroleptics). * Other acute or chronic psychiatric disorder (e.g. psychosis, somatoform disorder, alcohol or drug abuse disorder) * Cognitive impairment (MoCA score \< 25) * MADRS item 10 \> 1 (suicidal tendency) * Risk of lowered seizure threshold (due to e.g. sleep deprivation, withdrawal of alcohol after alcohol abuse, hyponatraemia) * History of seizures * Acute cerebrovascular condition * Acute renal failure or severe renal insufficiency (creatinine clearance \< 30 ml/min per 1.73 m2) * Bradycardia \< 50/min during clinical examination. * History of malignant cancers * Walking problems (e.g. due to dizziness) * Other clinically significant concomitant disease states (e.g. hepatic dysfunction, cardiovascular disease, diabetes, asthma) * Clinically significant laboratory or ECG abnormality that could be a safety issue in the study * Severe somatic or neurological comorbidities * Smoking including all nicotine containing smoking systems and devices (\>10 cigarettes/units per day). Failure to withstand a test day without craving, due to regular consummation patterns. * Pregnancy or breast feeding. Intention to become pregnant during the study participation. * Known or suspected non-compliance * Inability to follow the procedures of the study, e.g. due to language or psychological problems of the participant * Participation in another study with an investigational drug within the 30 days preceding and during the present study * Enrolment of the investigator, his/her family members, employees and other dependent persons
Conditions Diffuse Large B Cell Lymphoma, High-grad...
Phase PHASE2
Enrollment 50
Locations 7 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to find out how many people with B-cell lymphoma who are at high risk for central nervous system/CNS relapse test positive for cerebral spinal fluid/CSF ctDNA but test negative for CNS involvement using standard tests. The study will also look at how often CNS relapse happens in people with and without detected CSF ctDNA.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Diagnostic Test: Cerebral Spinal Fluid ctDNA — MSK's Diagnostic Molecular Pathology core has developed and validated a CSF ctDNA assay which has been approved by New York State Department of Health as of 2019

Primary Outcomes

  • Incidence of positive cerebral spinal fluid/CSF ctDNA (up to 2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-12-11
Completion: 2027-12-11
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Memorial Sloan Kettering Cancer Center
Principal Investigators:
  • Jennifer Lue, MD (PRINCIPAL_INVESTIGATOR) - Memorial Sloan Kettering Cancer Center
Contact Information
Study Contact:
Jennifer Lue, MD
646-608-4160
luej@mskcc.org
Ariela Noy, MD
646-608-3727
noya@MSKCC.ORG
Jennifer Lue, MD
646-608-4160
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Interventions
  • Diagnostic Test: Cerebral Spinal Fluid ctDNA — MSK's Diagnostic Molecular Pathology core has developed and validated a CSF ctDNA assay which has been approved by New York State Department of Health as of 2019
Study Locations (7 sites)
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey 07920 United States
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey 07748 United States
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey 07645 United States
Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack, New York 11725 United States
Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York 10604 United States
Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York, New York 10065 United States
Memorial Sloan Kettering Nassau (Limited Protocol Activities), Rockville Centre, New York 11553 United States
Eligibility Criteria
Inclusion Criteria: * Signed Informed Consent. * Ability and willingness to comply with the requirements of the study protocol. * Age ≥ 18 years old. * Diagnosis of the following histologies according to the 2016 WHO Classification for Mature Lymphoid Neoplasms81 along with a specific high-risk criteria for CNS relapse if indicated as certain diagnoses in of themselves are high-risk alone: 1. Diffuse Large B-cell Lymphoma (DLBCL) with CNS IPI score ≥ 4. 2. Stage III/IV High Grade B-cell lymphoma (HGBCL) with MYC, BCL2, and/or BCL6 translocations 3. Primary DLBCL of Breast 4. Primary DLBCL of Testis 5. Primary Cutaneous DLBCL, Leg Type 6. Intravascular Large B-cell Lymphoma 7. Stage III/IV HIV-associated DLBCL 8. Double expressor DLBCL (co-expression of MYC ≥ 40% and BCL2 ≥ 50% without translocations) with a CNS IPI score ≥ 3 9. DLBCL with the following extranodal involvement AND CNS IPI score ≥ 3: i. Adrenal ii. Breast iii. Bone Marrow with pathological overt morphological involvement iv. Epidural/Paraspinal v. Nasal/parasinus with local invasion such as bone destruction vi. Renal viii. Uterine ix. Testis xi. Skull involvement without direct invasion into CNS/brain parenchyma * Transformed DLBCL from any indolent B-cell lymphoma is permitted (as long as there is no prior history of CNS involvement). * Planned to receive standard chemoimmunotherapy. * Patient is able to undergo lumbar puncture without any contraindications which include but are not limited to altered mental status, increased intracranial pressure due to any CNS lesion (mass, abscess), overlying skin infection at the site of LP, inability to safely access CSF due to lymphomatous involvement (i.e. epidural mass), or inability to hold antiplatelet or anticoagulation safely for the procedure to be performed. * No systemic therapy prior to study enrollment for an aggressive B-cell lymphoma is permitted. Treatment for a history of indolent lymphoma is permitted. Systemic corticosteroids are permitted (must be ≤7 days and tapered down to prednisone ≤ 20 mg oral/day or steroid equivalent by first day of anthracycline treatment). Clinical exceptions in regards to steroid management can be made after discussion with PI. * ECOG performance status of 0 to 2. Exclusion Criteria: * Active systemic therapy for another malignancy (other than indolent B-cell lymphoma) within 2 years; local/regional therapy with curative intent such as surgical resection or localized radiation within 2 years of treatment is permitted. * Active concurrent malignancy with the exception of basal cell or localized squamous cell skin carcinoma, localized prostate cancer, or other localized carcinomas such as carcinoma in situ of cervix, breast, or bladder. * Any uncontrolled illness that in the opinion of the investigator would preclude administration of curative intent chemoimmunotherapy (e.g. significant active infections, hypertension, angina, arrhythmias, pulmonary disease, or autoimmune dysfunction). * Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment, or any major episode of infection requiring treatment with IV antibiotics or hospitalization within 2 weeks prior to Cycle 1, Day 1. * Psychiatric illness or social situations that would limit the patient's ability to tolerate and/or comply with study requirements.
Conditions Advanced Triple-negative Breast Cancer
Phase PHASE2
Enrollment 150
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Phase II clinical trial of PD-L1 in combination with vinorelbine + cyclophosphamide + capecitabine (VEX) metronomic chemotherapy with or without radiotherapy for advanced triple-negative breast cancer.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Adebrelimab + VEX metronomic chemotherapy + radiotherapy — 1、Adebrelimab: 1200mg on day 1, every 3 weeks; 2、VEX Metronomic Chemotherapy: Vinorelbine 20mg orally, once every other day, Q3W Cyclophosphamide 50mg orally, once daily, Q3W Capecitabine 500mg orally, three times daily, Q3W
  • Drug: Adebrelimab + VEX metronomic chemotherapy — 1、Adebrelimab: 1200mg on day 1, every 3 weeks; 2、VEX Metronomic Chemotherapy: Vinorelbine 20mg orally, once every other day, Q3W Cyclophosphamide 50mg orally, once daily, Q3W Capecitabine 500mg orally, three times daily, Q3W

Primary Outcomes

  • Progression-Free Survival (24 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-09-10
Completion: 2028-09-10
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Contact Information
Study Contact:
Fei Ma 马
010-87788120
drmafei@126.com
01087788060
drmafei@126.com
Cancer Hospital, Chinese Academy of Medical Sciences
Fei Ma M.D.
86-10-87788060
drmafei@126.com
Cancer Hospital, Chinese Academy of Medical Sciences
Interventions
  • Drug: Adebrelimab + VEX metronomic chemotherapy + radiotherapy — 1、Adebrelimab: 1200mg on day 1, every 3 weeks; 2、VEX Metronomic Chemotherapy: Vinorelbine 20mg orally, once every other day, Q3W Cyclophosphamide 50mg orally, once daily, Q3W Capecitabine 500mg orally, three times daily, Q3W
  • Drug: Adebrelimab + VEX metronomic chemotherapy — 1、Adebrelimab: 1200mg on day 1, every 3 weeks; 2、VEX Metronomic Chemotherapy: Vinorelbine 20mg orally, once every other day, Q3W Cyclophosphamide 50mg orally, once daily, Q3W Capecitabine 500mg orally, three times daily, Q3W
Study Locations (2 sites)
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing Municipality 100021 China
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing Municipality 100021 China
Eligibility Criteria
Subjects are eligible to be included in the study only if all of the following criteria apply: 1. Male or female who is 18 years of age or older on the day of signing the informed consent form. 2. Subjects with metastatic triple-negative breast cancer, with clear clinical data records; specific reference to the "American Society of Clinical Oncology - College of American Pathologists (ASCO/CAP) guidelines." 3. Have received less than or equal to 1 line of chemotherapy for metastatic breast cancer; 4. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 as assessed within 10 days before the start of study treatment; 5. Subjects must have at least one measurable lesion present; specific reference to the "Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)" guidelines; 6. Subjects may have previously received treatment with anthracyclines (e.g., doxorubicin, epirubicin) and/or taxanes (e.g., paclitaxel, docetaxel) as follows: a) The subject has used anthracyclines and/or taxanes during adjuvant and/or neoadjuvant therapy before breast cancer recurrence. b) The subject has experienced treatment failure during or after chemotherapy based on anthracyclines and/or taxanes. c) According to the investigator's judgment, the Subject is not suitable for anthracyclines and/or taxanes-based chemotherapy as a first-line treatment option. 7. Female subjects are not pregnant, not lactating, and agree to use necessary contraceptive measures. 8. Subjects are able to sign an informed consent form to participate in the study. 9. Have appropriate organ function, as detailed in Table 1; all screening laboratory tests should be completed within 10 days before the start of study treatment.